Ivermectin, Hydroxychloroquine drugs dropped from Covid 19 treatment, by ICMR
New Delhi: Fri, 24 Sep 2021 00:00:08, by: Deepak Kumar

The Indian Council of medical research’s (ICMR) Covid-19 National Task Force Joint Monitoring Group dropped the usage of Ivermectin and Hydroxychloroquine (HCQ) drugs from the revised clinical guidelines for the management of Covid-19 patients.

The new guideline however mentions the usage of Remdesivir and Tocilizumab in some specific circumstances.

Among the other key guidelines, the usual has been kept, like wearing a mask, social distancing and hand hygiene.

The guidelines suggest a moderate usage of drugs like Remdesivir in certain cases of moderate to severe cases on supplemental oxygen and within 10 days of the onset of symptoms.

While for the usage of Tocilizumab the guidelines suggest the usage of the medicine only in severe cases of Covid-19, and preferably within 24-48 hours of the onset of severe disease or ICU admission.

For mild cases, the guidelines ask to maintain physical distance, usage of mask and a strict adherence to hand hygiene.

The guideline further suggested that symptomatic patients may take antipyretic, antitussive and multivitamins, however, are asked to seek immediate medical attention if they experience trouble in breathing or a high grade of fever or severe cough, which are particularly last for more than 5 days.

Methylprednisolone injection and Anticoagulation medicine have been suggested for patients experiencing moderate disease and with SpO2 level 92-96 per cent, while 88-92 per cent for patients with Chronic obstructive pulmonary disease.

As per the guidelines, for severe cases of Covid-19, patients are suggested to be given NIV, Helmet or face mask interface depending on availability, especially in patients with increasing oxygen requirement, if breathing work is low.

"Consider the use of HFNC in patients with increasing oxygen requirement, Intubation should be prioritized in patients with high work of breathing /if NIV is not tolerated and Use conventional ARDSnet protocol for ventilatory management” it added.

The guidelines also said to take Methylprednisolone injection of 1 to 2 mg in two doses usually for a duration of 5 to 10 days.

The guideline informs that the severe disease and mortality risks are higher for people in their 60s, or with Cardiovascular disease, hypertension, Coronary artery disease, Diabetes mellitus, Chronic lung/kidney/liver disease, Cerebrovascular disease, Obesity and other immunocompromised states.

Recent Union government data has suggested that 66% of the eligible population has been vaccinated with at least one dose, while around 23% of the eligible population have been inoculated with both doses, with the Vaccination drive running on full force in the country.

In the run-up to the Festive season, India recorded a significant increase in daily Coronavirus infections, with new cases surpassing 30,000 for the second time on Friday. According to data released by the Union Health Ministry on Friday, India recorded 31,382 new Coronavirus infections in the past 24 hours, bringing the total number of Covid-19 infections to 3,35,94,803, while active cases fell to 3,00,162, the lowest level in 188 days. With 318 more deaths, the Covid-19 death toll now stands at 4,46,368. Active cases now account for 0.89 per cent of overall infections, the lowest level since March 2020, according to data from the Ministry of Health.

Author: Deepak Kumar

Deepak Kumar is Science Graduate from Delhi University with more than 17 years of experience in Media and Technical field. With a background in Science and Media field, Deepak has been offering services in the media houses. He has worked as director and chief in many companies. During his journalistic career, he has achieved many milestones working in various organisations. As a technical writer, he is of scientific bend of mind and has done many glorious stories in the field during the career.

Address: G-26/128, Sector-3, Rohini Delhi - 110085 India.

Email: deepak@crdb.org

Phone: +91 9313063554